A Phase 1 interventional study of LY3971297 and Placebo in Healthy, Obesity and Hypertension, sponsored by Eli Lilly and Company. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 67th largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 40 in phase 1, and was the 44th registered.
11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Eli Lilly and Company · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 21 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 267 across the 117 interventional studies. Of the 62 that completed or were terminated, 29 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
29 of the studies in Obesity by Eli Lilly and Company that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
Add all 29 to your calendar (.ics) → With an account.
Among the 118 studies in Obesity by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending doses of LY3971297 administered subcutaneously (SC) in healthy participants
Drug: LY3971297
Multiple ascending doses of LY3971297 administered SC in healthy participants
Drug: LY3971297
Multiple ascending doses of LY3971297 administered SC in healthy Chinese participants
Drug: LY3971297
Multiple ascending doses of LY3971297 administered SC
Drug: LY3971297
Multiple doses of LY3971297 administered SC in healthy Japanese participants
Drug: LY3971297
Placebo administered SC
Drug: Placebo
Single doses of LY3971297 administered intravenously (IV) in healthy participants
Drug: LY3971297 IV
Multiple doses of LY3971297 administered SC
Drug: LY3971297
Administered SC
Administered SC
Administered IV
Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Part A and F: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline (Day of Exposure) to Day 29 post-dose
Part B, C, D, E, & G: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Part B, C, D, E, \& G: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline (Day of Exposure) to Day 57 post-dose
Part F: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297
Part F: PK: AUC of LY3971297
Time frame: Baseline Up to Day 29 post-dose for Part F
Part F: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297
Part F: PK: Cmax of LY3971297
Time frame: Baseline Up to Day 29 post-dose for Part F
Part B, C, D, E, and G: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297
Part B, C, D, E, and G: PK: AUC of LY3971297
Time frame: Predose on day 1 up to 29 days post-dose for Part A and pre-dose on day 1 up to 57 days post-dose for Part B, C, D, E, and G
Part B, C, D, E, and G: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297
Part B, C, D, E, and G: PK: Cmax of LY3971297
Time frame: Predose on day 1 up to 29 days post-dose for Part A and pre-dose on day 1 up to 57 days post-dose for Part B, C, D, E, and G
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Aug 2026, 32 months.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 32 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.